Email: cspc@cspc.cn
News
News Center
Dec. 12
2025
VOLUNTARY ANNOUNCEMENT - NEW INDICATION FOR DUOENYI (IRINOTECAN HYDROCHLORIDE LIPOSOME INJECTION) OBTAINS MARKETING APPROVAL
Dec. 10
VOLUNTARY ANNOUNCEMENT - RECOMBINANT FULLY HUMAN ANTI-ACTRIIA/IIB MONOCLONAL ANTIBODY (JMT206) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Dec. 08
VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTS SECOND MARKETING AUTHORISATION APPLICATION FOR SEMAGLUTIDE INJECTION
Dec. 05
VOLUNTARY ANNOUNCEMENT - GLP-1/GIP RECEPTOR DUAL-BIASED AGONIST POLYPEPTIDE INJECTION (SYH2069 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Dec. 03
VOLUNTARY ANNOUNCEMENT - A SELECTIVE 5-HT2A RECEPTOR AGONIST (SYH2056 TABLETS) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Nov. 26
VOLUNTARY ANNOUNCEMENT - RECOMBINANT FULLY HUMAN ANTI-ACTRIIA/IIB MONOCLONAL ANTIBODY (JMT206) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
